Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Meiyuan Dong, Huiling Chen, Song Wen, Yue Yuan, Liling Yang, Yanyan Li, Xinlu Yuan, Dongxiang Xu & Ligang Zhou. (2023) The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance. Diabetes, Metabolic Syndrome and Obesity 16, pages 425-435.
Read now
Read now
Articles from other publishers (37)
Salvatore Greco, Vincenzo M. Monda, Giorgia Valpiani, Nicola Napoli, Carlo Crespini, Fabio Pieraccini, Anna Marra & Angelina Passaro. (2023) The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study. Biomedicines 11:8, pages 2292.
Crossref
Crossref
Vartika Srivastava, Sougata SarkarRatikanta Tripathy, Chaitali Pattanayak & Mangala Charana Das. (2023) Cost-effective Analysis of Prescribed Oral Hypoglycemic Agents amongst Pre-obese and Obese Diabetic Patients in a Tertiary Care Hospital in Odisha. Global Journal of Medical, Pharmaceutical, and Biomedical Update 18, pages 13.
Crossref
Crossref
Alessia d’Aiello, Alice Bonanni, Ramona Vinci, Daniela Pedicino, Anna Severino, Antonio De Vita, Simone Filomia, Mattia Brecciaroli & Giovanna Liuzzo. (2023) Meta-Inflammation and New Anti-Diabetic Drugs: A New Chance to Knock Down Residual Cardiovascular Risk. International Journal of Molecular Sciences 24:10, pages 8643.
Crossref
Crossref
Jiaqiang Wu, Kangping Yang, Hancheng Fan, Meilin Wei & Qin Xiong. (2023) Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus. Frontiers in Endocrinology 14.
Crossref
Crossref
Belén Picatoste, Isabel Cerro-Pardo, Luis M. Blanco-Colio & Jose L. Martín-Ventura. (2023) Protection of diabetes in aortic abdominal aneurysm: Are antidiabetics the real effectors?. Frontiers in Cardiovascular Medicine 10.
Crossref
Crossref
Xindong Liu, Ying Chen, Tao Liu, Ling Cai, Xiaofeng Yang & Chuan Mou. (2023) The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Frontiers in Endocrinology 14.
Crossref
Crossref
V. N. Karetnikova, A. A. Kchorlampenko, A. M. Kochergina, A. V. Osokina, O. V. Gruzdeva, D. P. Golubovskaia & O. L. Barbarash. (2022) Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus. Kardiologiia 62:12, pages 64-72.
Crossref
Crossref
Yongting Zhao, Xiaofang Zhang, Haihai Liang & Lihong Wang. (2022) Antidiabetic agents: Do they hit the right targets?. Frigid Zone Medicine 2:4, pages 225-243.
Crossref
Crossref
Marina Nikolic, Jovana Novakovic, Galina Ramenskaya, Vladimir Kokorekin, Nevena Jeremic & Vladimir Jakovljevic. (2022) Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?. Diabetology & Metabolic Syndrome 14:1.
Crossref
Crossref
Yi-Hong Zeng, Sung-Chen Liu, Chun-Chuan Lee, Fang-Ju Sun & Jason J. Liu. (2022) Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin. Scientific Reports 12:1.
Crossref
Crossref
Micaela Gliozzi, Roberta Macrì, Anna Rita Coppoletta, Vincenzo Musolino, Cristina Carresi, Miriam Scicchitano, Francesca Bosco, Lorenza Guarnieri, Antonio Cardamone, Stefano Ruga, Federica Scarano, Saverio Nucera, Rocco Mollace, Irene Bava, Rosamaria Caminiti, Maria Serra, Jessica Maiuolo, Ernesto Palma & Vincenzo Mollace. (2022) From Diabetes Care to Heart Failure Management: A Potential Therapeutic Approach Combining SGLT2 Inhibitors and Plant Extracts. Nutrients 14:18, pages 3737.
Crossref
Crossref
Yuting Ma, Guangdong Zhang, Zenggguang Kuang, Qian Xu, Tongtong Ye, Xue Li, Na Qu, Fang Han, Chengxia Kan & Xiaodong Sun. (2022) Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease. Frontiers in Pharmacology 13.
Crossref
Crossref
Josué Manríquez-Núñez & Minerva Ramos-Gómez. (2022) Bioactive Compounds and Adipocyte Browning Phenomenon. Current Issues in Molecular Biology 44:7, pages 3039-3052.
Crossref
Crossref
Ryan Kurtz, Andrew Libby, Bryce A. Jones, Komuraiah Myakala, Xiaoxin Wang, Yichien Lee, Grace Knoer, Julia N. Lo Cascio, Michaela McCormack, Grace Nguyen, Elijah N. D. Choos, Olga Rodriguez, Avi Z. Rosenberg, Suman Ranjit, Christopher Albanese, Moshe Levi, Carolyn M. Ecelbarger & Blythe D. Shepard. (2022) Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice. International Journal of Molecular Sciences 23:10, pages 5675.
Crossref
Crossref
Binbin Xia, Wenjie Yang, Huazheng Liang, Sonia Liu, Devin Wang & Jun Huang. (2022) Cancer Prevention Effects of Foods, Food Groups, Nutrients, and Their Underlying Mechanisms. ACS Food Science & Technology 2:3, pages 437-454.
Crossref
Crossref
Mariam N. Rana & Ian J. Neeland. (2022) Adipose Tissue Inflammation and Cardiovascular Disease: An Update. Current Diabetes Reports 22:1, pages 27-37.
Crossref
Crossref
Jingwen Cheng, Weiwei Cai, Shiye Zong, Yun Yu & Fang Wei. (2021) Metabolite transporters as regulators of macrophage polarization. Naunyn-Schmiedeberg's Archives of Pharmacology 395:1, pages 13-25.
Crossref
Crossref
Jing Xu, Taro Hirai, Daisuke Koya & Munehiro Kitada. (2021) Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. Journal of Clinical Medicine 11:1, pages 137.
Crossref
Crossref
Reka Annamaria Schmiedt, Robert Aurelian Tiuca, Raluca Maria Tilinca, Lucia Mihaela Custura, Oana Detesan, Brigitta Iren Bacso, Bianca Larisa Abalasei, Andrew Corneliu Bell, Maria Alexandra Streza & Mariana Cornelia Tilinca. (2021) Insulin resistance as risk factor for the development of type 2 diabetes mellitus: a systematic approach. Acta Marisiensis - Seria Medica 67:4, pages 187-192.
Crossref
Crossref
Angelo Avogaro, Benedetta Bonora & Gian Paolo Fadini. (2021) Managing diabetes in diabetic patients with COVID: where do we start from?. Acta Diabetologica 58:11, pages 1441-1450.
Crossref
Crossref
Linxin Xu, Chaofei Xu, Xiangyang Liu, Xiaoyu Li, Ting Li, Xiaochen Yu, Mei Xue, Jing Yang, Constantine E. Kosmas, Dimitrios Moris, Fabian Sanchis-Gomar, Naofumi Yoshida, Nathan A. Berger, Wilbert S. Aronow, Bei Sun & Liming Chen. (2021) Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay/J Mice and Mouse Adipocytes. Frontiers in Physiology 12.
Crossref
Crossref
Kai-Fan Tsai, Yung-Lung Chen, Terry Ting-Yu Chiou, Tian-Huei Chu, Lung-Chih Li, Hwee-Yeong Ng, Wen-Chin Lee & Chien-Te Lee. (2021) Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. Antioxidants 10:8, pages 1166.
Crossref
Crossref
David Bode, Lukas Semmler, Christian U. Oeing, Alessio Alogna, Gabriele G. Schiattarella, Burkert M. Pieske, Frank R. Heinzel & Felix Hohendanner. (2021) Implications of SGLT Inhibition on Redox Signalling in Atrial Fibrillation. International Journal of Molecular Sciences 22:11, pages 5937.
Crossref
Crossref
You-Bin Lee, Da Hye Kim, Seon Mee Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Yong Gyu Park, Kyungdo Han & Hye Jin Yoo. (2020) Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study. Cardiovascular Diabetology 19:1.
Crossref
Crossref
David Feder, Marisa Regina de Fatima Veiga Gouveia, Tania Carmen Peñaranda Govato & Cristina De Zotti Nassis. (2020) SGLT2 Inhibitors and the Mechanisms Involved in Weight Loss. Current Pharmacology Reports 6:6, pages 346-353.
Crossref
Crossref
Chao-Yung Wang, Chun-Chi Chen, Mei-Hsiu Lin, Hui-Ting Su, Ming-Yun Ho, Jih-Kai Yeh, Ming-Lung Tsai, I-Chang Hsieh & Ming-Shien Wen. (2020) TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity. Biology 9:11, pages 369.
Crossref
Crossref
Yi-Chou Hou, Cai-Mei Zheng, Tzung-Hai Yen & Kuo-Cheng Lu. (2020) Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. International Journal of Molecular Sciences 21:21, pages 7833.
Crossref
Crossref
Yusuke Takeda, Keiichiro Matoba, Kensuke Sekiguchi, Yosuke Nagai, Tamotsu Yokota, Kazunori Utsunomiya & Rimei Nishimura. (2020) Endothelial Dysfunction in Diabetes. Biomedicines 8:7, pages 182.
Crossref
Crossref
Yinqiu Yang, Chenhe Zhao, Yangli Ye, Mingxiang Yu & Xinhua Qu. (2020) Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes. Frontiers in Endocrinology 11.
Crossref
Crossref
Bo Deng, Vitaliy Kireev, Kristina Melentyeva, Igor Kovalenko & Oleksandr Pakhomov. (2020) Histology of Cryopreserved Neonatal Rat Testes After Intratesticular Allotransplantation. Problems of Cryobiology and Cryomedicine 30:1, pages 034-046.
Crossref
Crossref
Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Eguchi Y, Okanoue T & Nakajima A. (2020) Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease. Diabetes Research: Open Access 2:S1, pages 17-25.
Crossref
Crossref
A. V. OnyschenkoO. V. SheshukovaO. Ye. Akimov. (2020) THE INFLUENCE OF OVERWEIGHT AND INFLAMMATION OF PERIODONTAL TISSUES ON THE ACTIVITY OF MARKER ENZYMES OF MACROPHAGES POLARIZATION IN THE ORAL FLUID OF PRIMARY SCHOOL-AGED CHILDREN. Bulletin of Problems Biology and Medicine 4:1, pages 356.
Crossref
Crossref
Kohshiro Hosokawa, Tomoaki Takata, Takaaki Sugihara, Tomomitsu Matono, Masahiko Koda, Tsutomu Kanda, Sosuke Taniguchi, Ayami Ida, Yukari Mae, Marie Yamamoto, Takuji Iyama, Satoko Fukuda & Hajime Isomoto. (2019) Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules. International Journal of Molecular Sciences 21:1, pages 190.
Crossref
Crossref
Rebeca OrtegaAida ColladoFrancisca SellesHerminia Gonzalez-NavarroMaria-Jesus SanzJosé T. RealLaura Piqueras. (2019) SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)–Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology 39:8, pages 1614-1628.
Crossref
Crossref
P. C. Lee, S. Ganguly & S.‐Y. Goh. (2018) Weight loss associated with sodium‐glucose cotransporter‐2 inhibition: a review of evidence and underlying mechanisms. Obesity Reviews 19:12, pages 1630-1641.
Crossref
Crossref
F. Bonnet & A.J. Scheen. (2018) Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes & Metabolism 44:6, pages 457-464.
Crossref
Crossref
Merlin C. Thomas & David Z. I. Cherney. (2018) The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61:10, pages 2098-2107.
Crossref
Crossref